Equasens Société anonyme Valuation
Is EQS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EQS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EQS (€42.6) is trading below our estimate of fair value (€106.06)
Significantly Below Fair Value: EQS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EQS?
Key metric: As EQS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is EQS's PE Ratio? | |
|---|---|
| PE Ratio | 15.2x |
| Earnings | €42.25m |
| Market Cap | €640.33m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.1x |
| Enterprise Value/EBITDA | 12.8x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does EQS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 36.2x | ||
CGM Cegedim | 75.8x | 49.8% | €152.9m |
MLLAB Media Lab | 57.9x | n/a | €5.3m |
EMEIS emeis Société anonyme | 0.6x | -108.0% | €942.5m |
GBT Guerbet | 10.4x | 18.3% | €341.1m |
EQS Equasens Société anonyme | 15.2x | 11.4% | €640.3m |
Price-To-Earnings vs Peers: EQS is good value based on its Price-To-Earnings Ratio (15.2x) compared to the peer average (36.2x).
Price to Earnings Ratio vs Industry
How does EQS's PE Ratio compare vs other companies in the European Healthcare Services Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: EQS is good value based on its Price-To-Earnings Ratio (15.2x) compared to the European Healthcare Services industry average (18.2x).
Price to Earnings Ratio vs Fair Ratio
What is EQS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.2x |
| Fair PE Ratio | 15.2x |
Price-To-Earnings vs Fair Ratio: EQS is good value based on its Price-To-Earnings Ratio (15.2x) compared to the estimated Fair Price-To-Earnings Ratio (15.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €42.60 | €62.00 +45.5% | 15.0% | €75.00 | €53.00 | n/a | 6 |
| Nov ’25 | €48.30 | €64.22 +33.0% | 17.1% | €83.00 | €54.00 | n/a | 6 |
| Oct ’25 | €50.40 | €69.50 +37.9% | 14.3% | €81.00 | €54.00 | n/a | 4 |
| Sep ’25 | €47.70 | €69.60 +45.9% | 12.7% | €81.00 | €54.00 | n/a | 5 |
| Aug ’25 | €46.65 | €70.98 +52.2% | 13.6% | €83.00 | €54.00 | n/a | 5 |
| Jul ’25 | €55.10 | €71.48 +29.7% | 10.6% | €83.00 | €58.00 | n/a | 6 |
| Jun ’25 | €61.60 | €70.07 +13.7% | 10.1% | €80.00 | €58.00 | n/a | 6 |
| May ’25 | €58.90 | €71.25 +21.0% | 11.2% | €82.50 | €59.00 | n/a | 6 |
| Apr ’25 | €51.30 | €71.55 +39.5% | 11.7% | €82.50 | €59.00 | n/a | 6 |
| Mar ’25 | €47.05 | €71.55 +52.1% | 11.7% | €82.50 | €59.00 | n/a | 6 |
| Feb ’25 | €52.90 | €78.65 +48.7% | 14.5% | €94.60 | €66.00 | n/a | 6 |
| Jan ’25 | €61.10 | €80.38 +31.6% | 14.6% | €94.60 | €66.00 | n/a | 5 |
| Dec ’24 | €57.80 | €83.38 +44.3% | 12.7% | €94.60 | €66.00 | n/a | 5 |
| Nov ’24 | €65.00 | €93.58 +44.0% | 7.9% | €105.00 | €85.00 | €48.30 | 5 |
| Oct ’24 | €72.90 | €94.12 +29.1% | 8.3% | €105.00 | €85.00 | €50.40 | 5 |
| Sep ’24 | €74.10 | €94.12 +27.0% | 8.3% | €105.00 | €85.00 | €47.70 | 5 |
| Aug ’24 | €82.90 | €95.00 +14.6% | 9.1% | €108.00 | €85.00 | €46.65 | 5 |
| Jul ’24 | €84.70 | €94.40 +11.5% | 8.3% | €105.00 | €85.00 | €55.10 | 5 |
| Jun ’24 | €79.60 | €94.40 +18.6% | 8.3% | €105.00 | €85.00 | €61.60 | 5 |
| May ’24 | €71.70 | €94.48 +31.8% | 6.6% | €100.00 | €85.00 | €58.90 | 4 |
| Apr ’24 | €71.70 | €94.48 +31.8% | 6.6% | €100.00 | €85.00 | €51.30 | 4 |
| Mar ’24 | €77.80 | €100.97 +29.8% | 6.9% | €110.00 | €92.90 | €47.05 | 3 |
| Feb ’24 | €74.50 | €99.10 +33.0% | 9.4% | €110.00 | €87.30 | €52.90 | 3 |
| Jan ’24 | €74.70 | €99.10 +32.7% | 9.4% | €110.00 | €87.30 | €61.10 | 3 |
| Dec ’23 | €76.60 | €99.10 +29.4% | 9.4% | €110.00 | €87.30 | €57.80 | 3 |
| Nov ’23 | €73.40 | €102.47 +39.6% | 13.2% | €120.10 | €87.30 | €65.00 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Laboratoires Euromedis Société anonyme
€13.6m
Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.
ALEMG
€4.77
7D
-8.6%
1Y
-1.4%
emeis Société anonyme
€942.5m
Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.
EMEIS
€5.86
7D
-9.0%
1Y
-98.8%
bioMérieux
€11.6b
Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
BIM
€98.35
7D
-3.9%
1Y
2.6%